How biomarkers will change psychiatry: From clinical trials to practice. Part I: Introduction

Journal of Psychiatric Practice

Volumn 18, Issue 2, 2012, Pages 118-121

  MacAluso, Matthew ^a   Preskorn, Sheldon H ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

Author keywords

atherosclerosis; biomarkers; clinical trials; positron emission topography; prolactin; saccadic eye movements

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CREATINE KINASE; CREATINE KINASE MB; DOPAMINE 2 RECEPTOR; HYDROCORTISONE; LOW DENSITY LIPOPROTEIN; MYOGLOBIN; NEW DRUG; PROLACTIN; SEROTONIN TRANSPORTER; THROMBOXANE; TROPONIN I; TROPONIN T;

ATHEROSCLEROSIS; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DEPRESSION; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; MENTAL DISEASE; MENTAL HEALTH RESEARCH; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PSYCHIATRY; RECEPTOR OCCUPANCY; REM SLEEP; REVIEW; RISK ASSESSMENT; SACCADIC EYE MOVEMENT; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE;

BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; HUMANS; MENTAL DISORDERS; PSYCHIATRY;

EID: 84858838507     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pra.0000413277.11091.25     Document Type: Review

References (13)

1. Reus VI, Joseph M, Dallman M. Regulation of ACTH and cortisol in depression. Peptides 1983;4:785-8.
2. Syvälahti E, Eskola J, Ruuskanen O, et al. Nonsuppression of cortisol in depression and immune function. Prog Neuropsychopharmacol Biol Psychiatry 1985;9:413-22.
3. Kaplan A. Blood tests for diagnosis of schizophrenia and depression? Psychiatric Times, August 10, 2011 (available at www.psychiatrictimes.com/ display/article/10168/1926061 ?pageNumber=1, accessed February 28, 2012).
4. Ganter B, Giroux CN. Emerging applications of network and pathway analysis in drug discovery and development. Curr Opin Drug Discov Devel 2008;11:86-94.
5. Wong DF, Tauscher J, Gründer G. The role of imaging in proof of concept for CNS drug discovery and development. Neuropsychopharmacology 2009;34:187-203.
6. Pani L, Pira L, Marchese G. Antipsychotic efficacy: Relationship to optimal D2-receptor occupancy. Eur Psychiatry 2007;22:267-75.
7. Sweeney JA, Bauer KS, Keshavan MS, et al. Adverse effects of risperidone on eye movement activity: A comparison of risperidone and haloperidol in antipsychotic-naive schizophrenic patients. Neuropsychopharmacology 1997;16: 217-28.
8. de Visser SJ, van der Post J, Pieters MS, et al. Biomarkers for the effects of antipsychotic drugs in healthy volunteers. Br J Clin Pharmacol 2001;512:119-32.
9. Leuchter AF, Cook IA, Marangell LB, et al. Comparative effectiveness of biomarkers and clinical indicators for predicting outcomes of SSRI treatment in major depressive disorder: Results of the BRITE-MD study. Psychiatry Res 2009;169:124-31.
10. Rijnbeek B, de Viseer SJ, Franson KL, et al. REM sleep effects as a biomarker for the effects of antidepressants in healthy volunteers. J Psychopharmacol 2003;17:196-203.
11. Steiger A, Kimura M. Wake and sleep EEG provide biomarkers in depression. J Psychiatr Res 2010;44:242-52.
12. Preskorn SH. The use of biomarkers in psychiatric research: How serotonin transporter occupancy explains the doseresponse curves of SSRIs. J Psychiatr Practice 2012;18: 38-45.
13. Preskorn SH. What do the terms "drug-specific response/ remission rate" and "placebo" really mean? J Psychiatr Pract 2011;17:420-4.